← Leaderboards
Daniel W Nixon
Medical University Of South Carolina
$17,202,065
Attributed
$17,202,065
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $570.3K · FY2005–10$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$30,252,568 · 10
By mechanism
R01$16,979,710 · 1
P30$13,050,503 · 1
M01$222,355 · 8
Top collaborators
No co-investigators on record.
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Carla Kmett Danielson$14,901,808
- Jean Marie Ruddy$882,360
- L. Lyndon Key$1,083,877
- Julie Chao$9,369,252
- Ethan Michael Anderson$1,535,739
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchNutrition Related TagHuman SubjectCancer PreventionNutrient Intake ActivityHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyBreast NeoplasmsNeoplasm /Cancer Relapse /RecurrenceFemaleClinical TrialsResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabaseResourcesSourceInstitutionGrantFundingNeoplasm /CancerUnited States National Institutes Of HealthFoodFruitBiomedical FacilityBioenergetics
Grant awards (27)
STUDY A5235: A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF MINOCYCLINE IN THE$10,190
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: A PHASE III COMPARATIVE STUDY OF THREE NON-NUCLEOSIDE REVERSE TR$9,463
M01 · FY2010 · RR · contact PI
START- STRATEGIC TIMING OF ANTIRETROVIRAL THERAPY$726
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PHASE III STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS W/$41,546
M01 · FY2009 · RR · contact PI
AN INTERNATIONAL, PHASE II, MULTI-SITE, OPEN-LABEL, RANDOMIZED STUDY OF ALDES$133,346
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PHASE III STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS W/$27,084
M01 · FY2008 · RR · contact PI
CANCER CENTER SUPPORT GRANT$570,265
P30 · FY2005 · CA
CANCER CENTER SUPPORT GRANT$2,713,037
P30 · FY2004 · CA
LOW FAT DIET AND BREAST CANCER RECURRENCE--OUTCOME TRIAL$318,884
R01 · FY2004 · CA
LOW FAT DIET AND BREAST CANCER RECURRENCE--OUTCOME TRIAL$3,907,830
R01 · FY2003 · CA
CANCER CENTER SUPPORT GRANT$2,632,649
P30 · FY2003 · CA
LOW FAT DIET AND BREAST CANCER RECURRENCE--OUTCOME TRIAL$4,462,642
R01 · FY2002 · CA
CANCER CENTER SUPPORT GRANT$2,554,404
P30 · FY2002 · CA
ELLAGIC ACID FROM DIETARY INTAKE OF RASPBERRIES$0
M01 · FY2002 · RR
METABOLIC OVERDRIVE AND BREAST CANCER RECURRENCE$0
M01 · FY2002 · RR
LOW FAT DIET AND BREAST CANCER RECURRENCE--OUTCOME TRIAL$4,076,562
R01 · FY2001 · CA
CANCER CENTER SUPPORT$2,311,872
P30 · FY2001 · CA
ELLAGIC ACID FROM DIETARY INTAKE OF RASPBERRIES$0
M01 · FY2001 · RR
ELLAGIC ACID FROM DIETARY INTAKE OF RASPBERRIES$0
M01 · FY2001 · RR
METABOLIC OVERDRIVE AND BREAST CANCER RECURRENCE$0
M01 · FY2001 · RR
METABOLIC OVERDRIVE AND BREAST CANCER RECURRENCE$0
M01 · FY2001 · RR
METABOLIC OVERDRIVE AND BREAST CANCER RECURRENCE$0
M01 · FY2001 · RR
ELLAGIC ACID FROM DIETARY INTAKE OF RASPBERRIES$0
M01 · FY2001 · RR
LOW FAT DIET AND BREAST CANCER RECURRENCE--OUTCOME TRIAL$4,213,792
R01 · FY2000 · CA
CANCER CENTER SUPPORT$2,268,276
P30 · FY2000 · CA
ELLAGIC ACID FROM DIETARY INTAKE OF RASPBERRIES$0
M01 · FY2000 · RR
METABOLIC OVERDRIVE AND BREAST CANCER RECURRENCE$0
M01 · FY2000 · RR